Clinical Trial Update: Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients [Phase 1]

View source ↗

Summary

Completed Phase I dose-escalation trial of an allosteric AKT 1/2 inhibitor sponsored by Bayer in patients with cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Bayer AKT1/2 allosteric inhibitor (experimental)

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED